Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced @entity2 with XXXX .

@entity1 @entity137 @entity16 @entity2 @entity900 @entity358 @entity902 @entity456
BACKGROUND: We conducted a trial of a new less invasive, locoregional modality for @entity2 with @entity456 . This study was planned to investigate the feasibility, safety, and pharmacokinetics of pleural perfusion thermochemotherapy (PPTC) under video-assisted thoracoscopic surgery (VATS) and its modified method with a short perfusion time for preventing @entity16 to the lung during the procedure. METHODS: Seventeen @entity1 , 59 to 79 years old, underwent surgical resection of the primary lesions and PPTC under VATS without thoracotomy. All had @entity456 with @entity2 proven before the treatment. PPTC consists of irrigating the pleural space with 42 degrees C saline solution containing @entity900 (200 mg/m(2)) using a devised circuit. The time for perfusion was two hours in 10 @entity1 (group L), and one hour in 7 @entity1 (group S). RESULTS: All @entity1 successfully completed this treatment with acceptable @entity137 . The pharmacokinetic analysis showed that high @entity902 levels for the regional pleural exposure, which was 20- to 40-fold greater than those for the plasma in both groups. These values were equivalent between the groups, although the levels for the plasma were higher in group L than in group S. @entity358 was seen in 4 @entity1 with no serious conditions in group L, and none in group S. The median survival for the L and S groups was 17 and 19 months, respectively. CONCLUSIONS: This less invasive modality seems to offer a safe, feasible, and pharmacokinetically advantageous procedure to have excellent local control for @entity2 with @entity456 .
